Functional differences in mesenchymal stromal cells from human dental pulp and periodontal ligament

Anoop Babu Vasandan, Shilpa Rani Shankar, Priya Prasad, Vulugundam Sowmya Jahnavi, Ramesh Ramachandra Bhonde, Susarla Jyothi Prasanna *

School of Regenerative Medicine (SORM), Manipal University, Bangalore, India

Received: July 6, 2013; Accepted: October 23, 2013

Abstract

Clinically reported reparative benefits of mesenchymal stromal cells (MSCs) are majorly attributed to strong immune-modulatory abilities not exactly shared by fibroblasts. However, MSCs remain heterogeneous populations, with unique tissue-specific subsets, and lack of clear-cut assays defining therapeutic stromal subsets adds further ambiguity to the field. In this context, in-depth evaluation of cellular characteristics of MSCs from proximal oro-facial tissues: dental pulp (DPSCs) and periodontal ligament (PDLSCs) from identical donors provides an opportunity to evaluate exclusive niche-specific influences on multipotency and immune-modulation. Exhaustive cell surface profiling of DPSCs and PDLSCs indicated key differences in expression of mesenchymal (CD105) and pluripotent/multipotent stem cell–associated cell surface antigens: SSEA4, CD117, CD123 and CD29. DPSCs and PDLSCs exhibited strong chondrogenic potential, but only DPSCs exhibited adipogenic and osteogenic propensities. PDLSCs expressed immuno-stimulatory/immune-adhesive ligands like HLA-DR and CD50, upon priming with IFN\(\gamma\), unlike DPSCs, indicating differential response patterns to pro-inflammatory cytokines. Both DPSCs and PDLSCs were hypo-immunogenic and did not elicit robust allogeneic responses despite exposure to IFN\(\gamma\) or TNF\(\alpha\). Interestingly, only DPSCs attenuated mitogen-induced lympho-proliferative responses and priming with either IFN\(\gamma\) or TNF\(\alpha\) enhanced immuno-modulation capacity. In contrast, primed or unprimed PDLSCs lacked the ability to suppress polyclonal T cell blast responses. This study indicates that stromal cells from even topographically related tissues do not necessarily share identical MSC properties and emphasizes the need for a thorough functional testing of MSCs from diverse sources with respect to multipotency, immune parameters and response to pro-inflammatory cytokines before translational usage.

Keywords: mesenchymal stromal cells • dental pulp stromal cells • pro-inflammatory cytokines • immune properties • periodontal ligament stromal cells • differentiation • stem cells

Introduction

Since the advent of bone marrow stromal cells (BMSCs) as off-the-shelf cells for cellular therapy, there had been a hurried need for a more easily accessible stromal stem cell/progenitor replacement, which does not involve invasive processing. Mesenchymal stromal cells (MSCs) have now been obtained and identified from most tissues by extrapolating the ‘gold standard’ criteria christened for BMSCs. Despite these claims, the MSC phenotype still remains very confounding, defined minimally by absence of haematopoietic markers, the presence of a set of mesenchymal markers and multi-lineage differentiation potential into connective tissue lineages. These criteria were set by the International Society for Cellular Therapy (ISCT) to ascertain uniformity for defining the MSC phenotype across different culture conditions, isolation procedures and tissue sources [1]. However, increasing evidence substantiates the fact that these definitions are not strictly followed for all tissue-derived MSCs with differences in the functional potency within the mesenchymal lineages, even though the basic surface phenotype remains conserved [2–5]. Ex vivo expanded MSCs are heterogeneous subsets, with respect to their stage of maturity/self-renewal along the differentiation hierarchy. This differentiation hierarchy could be influenced by tissue-specific niches, where MSCs are acclimatized in vivo. The dental pulp mesenchyme is surrounded by rich vasculature and is termed ‘ecto-mesenchyme’, owing to its early neural-crest origin, whereas periodontal tissue is...
close contact with the dentin and the alveolar bone [6, 7]. These fac-
etics can impact MSC properties. Thus, the present study attempts to evaluate, in-depth, the mesenchymal properties of MSCs derived from geographically nearby dental tissues, dental pulp stromal cells (DPSCs) and periodontal ligament stromal cells (PDLSCs), which in vivo occupy different physiological niches. Cosmetic impaction allows for isolation of both DPSCs and PDLSCs from the same individual, negating sample-specific variations, thus providing a unique opportunity to evaluate exclusive niche-specific differences in MSC properties.

Despite change in nomenclature of MSC from multipotent ‘Mesenchymal stem cells’, which have capacity to trans-differentiate to non-
mesenchymal lineages, to ‘Mesenchymal stromal cells’, which have capacity to correct Graft versus host disease (GVHD), further sub-
stantiating the role of response of MSCs to inflammatory cytokines in mediating their clinical benefits [10]. The immune properties of BMSCs are well studied, but MSCs from dental tissues have not been thoroughly profiled for their immune properties, and their response to pro-inflammatory cytokines, in particular, is not surveyed. As inflam-
ation is an inseparable component in disease and transplantation, one key objective of this study is to assess the immune properties of DPSCs and PDLSCs in presence of key pro-inflammatory cytokines like IFN-γ and TNF-α before transplantation regimens are planned with these cells.

Materials and methods

Isolation of human DPSCs and PDLSCs

Human dental pulp and periodontal ligament tissue were isolated from healthy impacted third molar teeth extracted for cosmetic purposes after obtaining informed consent, as per approved guidelines of the Institutional Ethics Committee. The age group of the participants ranged from 17 to 28 years. The tooth was thoroughly washed with dulbecco’s phos-
phate buffered saline (DPBS) (Gibco, Grand Island, NY, USA) containing Antibiotic–Antimycotic (Gibco) and the periodontal ligament tissue was scraped for further processing. The tissue was teased and digested over-
night with 0.5 mg/ml Collagenase Blend type H (Sigma-Aldrich, St.
Louis, MO, USA) in a 37°C incubator. The digested tissue was washed with DPBS and plated in KO DMEM™ (Gibco) supplemented with 10% FBS (HyClone, Thermo Scientific, Mordialloc, Vic., Australia), 1× Gluta-
Max (Gibco) and 1× Antibiotic–Antimycotic. The floating debris was removed after 24 hrs and the adherent cells were allowed to grow till confluence and passaged further in the same medium.

To extract dental pulp from the same tooth, the tooth was cut open with a high-speed dental drill in a sterile environment; the pulp was minced and digested for 3 hrs in 2 mg/ml of Collagenase Blend type H. The digested pulp was washed with DPBS and plated in KO DMEM™ supplemented with 10% FBS, 1× GlutaMax (Gibco) and 1× Antibiotic–
Antimycotic-containing media and allowed to reach confluence before passaging. For all the experiments, cells within passage 6 were used. Comparisons between DPSCs and PDLSCs were carried out at identical passages and from the same tooth tissue to minimize donor- and passage-dependent variations.

Differentiation of DPSCs and PDLSCs

Confluent MSC cultures were subjected to osteogenic induction in KO DMEM media containing 10 nM Dexamethasone (Sigma-Aldrich), 50 μM of ascorbic acid (Sigma-Aldrich), 10 mM β-glycerophosphate (Sigma-Aldrich), 10% FBS and 1× GlutaMAX. Mineralization was con-

Confirmed by Von Kossa staining [11].

Adipogenic ability of MSCs was evaluated by exposing confluent cul-
tures to KO DMEM media with 10% FBS, 1 μM Dexamethasone, 0.5 mM Isobutyl-methyl-Xanthine (IBMX; Sigma-Aldrich), 1 μg/ml Insul-
in (Sigma-Aldrich) and 100 μM Indomethacin (Sigma-Aldrich). Oil Red
O (Sigma-Aldrich) staining was performed to detect oil deposition [11].

Chondrogenic potential was evaluated by culturing confluent MSCs in KO DMEM media with 10% FBS, 1 mM Sodium pyruvate (Gibco), 0.1 μM Dexamethasone, 10 ng/ml of TGFβ1 (Sigma-Aldrich), 50 ng/ml of Ascorbic acid, 1× Insulin-Transferrin-Sodium Selenite pre-mix (Sigma-Aldrich) and 4 mM Proline (Sigma-Aldrich). Chondrogenic induc-
dation was assessed by Safranin O staining in monolayer cultures [11].

Mesenchymal stem cells at passage 4 were used for testing the tri-
lineage differentiation potential. Induction media was changed every 4th day till 16 and 18 days before molecular analysis and functional assessment respectively.

Flow cytometry

Dental pulp stromal cells and PDLSCs between passages 4–6 were trypsinized and re-suspended in DPBS with 0.5% BSA (Sigma-Aldrich) and incubated at 4°C with specific antibodies for 45 min. Cells were sub-
sequently washed in DPBS containing 0.01% azide and fixed with 1% paraformaldehyde and stored at 4°C till further analysis. For basic mesenchymal characterization, mouse anti-human CD73-PE, CD90-PE, CD105-PE, CD34-PE, CD45-PE, CD19-PE, CD14-PE, HLA-DR-FITC anti-
body conjugates and the relevant isotype controls (mouse IgG1

–

FITC, mouse IgG1

–

Dental pulp stromal cells and PDLSCs between passages 4–6 were trypsinized and re-suspended in DPBS with 0.5% BSA (Sigma-Aldrich) and incubated at 4°C with specific antibodies for 45 min. Cells were sub-
sequently washed in DPBS containing 0.01% azide and fixed with 1% paraformaldehyde and stored at 4°C till further analysis. For basic mesenchymal characterization, mouse anti-human CD73-PE, CD90-PE, CD105-PE, CD34-PE, CD45-ITC, CD19-PE, CD14-PE, HLA-DR-ITC anti-
body conjugates and the relevant isotype controls were obtained from BD Pharmingen. Detailed characterization for markers expressed on multipotent/pluripotent cell types included staining with mouse anti-human CD117-PE, CD123-PE, CD106-ITC, CD31-PE, SSEA4-ITC, CD13-PE, CD29-ITC and CD9-ITC antibody conjugates and acquisition with a BD LSR II flow cytometer. Percentage positivity for each marker was calcu-
lated by gating with respect to the relevant isotype control staining by using the FACS Diva software (BD Biosciences, San Jose, CA, USA).

To check the expression of immune-relevant ligands on DPSCs and PDLSCs upon exposure to pro-inflammatory cytokines, both MSCs were untreated or stimulated with either 150 U/ml of IFN-γ (Sigma-Aldrich) or 10 ng/ml of TNF-α (Sigma-Aldrich) for 72 hrs, trypsinized and stained with mouse anti-human HLA-ABC-ITC, HLA-DR-ITC, CD80-ITC, CD86-PE, CD95-ITC, CD50-ITC, CD54-PE, CD11a-PE, CD11b-APC and CD166-PE antibody conjugates and the relevant isotype controls (mouse IgG1x FITC, mouse IgG1x PE and mouse IgG1x APC). All antibodies used for flow cytometry analysis were obtained from BD Pharmingen. Cells were acquired on a BD FACS CALIBUR and the overlays were performed with Cell Quest Pro software (BD Biosciences).
Gene expression analysis in differentiated cultures

Total RNA was extracted from differentiated cultures by using RNeasy PLUS mini kit from Qiagen. 0.5 μg of RNA was reverse-transcribed by using Superscript III First strand synthesis kit (Invitrogen, Carlsbad, CA, USA) as per manufacturer’s instructions. Diluted cDNA was amplified by polymerase chain reaction by using specific primer sets in a Veriti 96-well thermo-cycler (Applied Biosystems, Scoresby, Vic., Australia). The cycling conditions included an initializing temperature of 95°C for 5 min followed by denaturation at 94°C for 30 s, annealing at specific annealing temperatures for 30 s, extension at 72°C for 30 s and final extension at 72°C for 10 min. 30-cycle amplification was set to assure the assessment of PCR products at non-saturating PCR conditions for all genes except SOX9 and ACAN. The primers and their specific annealing temperatures are listed in Table 1. mRNA expression of housekeeping gene, GAPDH, was used as an internal loading control.

One way mixed lymphocyte reactions

To test the immunogenicity of DPSCs and PDLSCs, 0.1 × 10⁵ (mentioned as +0.1% SC condition) or 0.01 × 10⁵ (mentioned as +0.01% SC condition) mitomycin C-fixed stromal cells between passages 3–6 were co-cultured with 1.0 × 10⁵ allogeneic peripheral blood mononuclear cells (PBMCs) for 6 days. Subsequently, BrdU incorporation assay was performed to check for lymphoproliferative responses elicited against stimulator stromal cells. BrdU uptake was measured by using BrdU cell proliferation assay kit (Calbiochem, San Diego, CA, USA) as per manufacturer instructions. Responses against stimulator mitomycin C-fixed allogeneic PBMCs were used as a positive control for the mixed lymphocyte reaction (MLR) assay.

Relative proliferation index was calculated after normalizing the BrdU uptake of MSCs (DPSCs or PDLSCs) with positive control allogeneic PBMCs (where robust MLR response was noted) from the same donor, which was considered to be 100%.

Stimulator allogeneic PBMCs, as well as stimulator allogeneic MSCs, were fixed with 10 μg/ml of mitomycin C for 2 hrs to arrest proliferation of stimulator cells in the one way MLR. Mitomycin C-fixed cells were washed with DPBS containing 10% FBS before setting up the MLR.

Mitogen-induced lympho-proliferative responses

For mitogenic stimulation experiments, PBMCs (1.0 × 10⁵ cells/ml) were stimulated with 20 μg/ml of Phytohaemagglutinin (PHA; Biological Industries, Kibbutz Beit-Haemek, Israel) for 72 hrs in the presence and absence of co-cultured mitomycin C-fixed stromal cells at different dose ratios [0.1 × 10⁵ cells/ml (mentioned as +0.1% condition), 0.01 × 10⁵ cells/ml (mentioned as +0.01% condition)] in 96 well plates and T cell blasts appearing were captured by using a Nikon Eclipse TE2000-U microscope (Melville, NY, USA). Phytohaemagglutinin-induced proliferative responses were quantified by using a BrdU incorporation assay as previously mentioned. Relative proliferation index (RPU) in stromal cell co-cultures was calculated by normalizing the BrdU uptake with PHA-induced PBMC cultures alone, which was considered to be 100%.

For co-cultures involving IFNγ- and TNFα-primed stromal cells and PBMCs, DPSCs or PDLSCs were pretreated with 150 U/ml of IFNγ or 10 ng/ml of TNFα for 72 hrs. The primed MSCs were mitomycin C-fixed, washed and then co-cultured with PHA-stimulated PBMCs at different dose ratios as mentioned above. Mesenchymal stromal cells, both unprimed and primed, were fixed with 10 μg/ml of mitomycin C for 2 hrs, washed and then used for the lympho-proliferation assay.

Statistical analysis

All values represent the mean values of at least three independent experiments and the corresponding standard error (SEM). Data between different test samples were compared by using Student’s t-test. A P < 0.05 (*) was considered statistically significant and a P < 0.001 (**) was considered very significant.

Results

Characterization of DPSCs and PDLSCs for mesenchymal and multipotent/pluripotent stem cell–associated antigens

Stromal isolates from dental pulp and periodontal ligament between passages 3–6 were characterized for markers, as specified by ISCT
guidelines [1]. Both DPSCs and PDLSCs lacked expression of haematopoietic markers: CD34 (primitive haematopoietic progenitor marker), CD45 (pan-leucocyte marker), CD14 (monocyte/macrophage marker) and CD19 (B cell marker), the absence of which is critical for defining a Mesenchymal stromal cell. HLA-DR, a key marker involved in T cell recognition, was absent in both the MSCs (Fig. 1A). Robust expression of CD73 and CD90 (Thy-1; >95% positivity) was noted in both MSCs. CD105 (Endoglin), a component of the receptor complex of Transforming growth factor-beta, TGFβ, was expressed robustly in DPSCs (>90% positivity), but PDLSCs exhibited a very weak expression pattern (Fig. 1A).

Mesenchymal stromal cells are mostly perivascular with respect to their tissue distribution and bone marrow MSCs and UC-MSCs have been reported to have strong haematopoietic engraftment support abilities [12, 13]. Thus, multipotent stromal/myeloid progenitors from few sources are reported to express CD117 (SCF R, c-kit), CD123 (IL-3 R) as well as CD106 (VCAM-1) [14, 15]. Dental pulp stromal cell expressed CD117 and CD123, but only bleak expression of these markers was noted on PDLSCs. Both DPSCs and PDLSCs lack expression of surface antigens present on activated and differentiated endothelial cells like CD106 and CD31 respectively (Fig. 1B). Markers strongly expressed on pluriotent cell types like SSEA4 (stage-specific embryonic antigen-4), CD13 (aminopeptidase N), CD29 (Integrin α1) and CD9 (tetraspanin receptor implicated in early developmental events) were expressed in PDLSCs (Fig. 1C). Periodontal ligament stromal cells expressed only CD13 and CD9 and lacked expression of SSEA4 and CD29 (Fig. 1C).

Thus, it appears that stromal cells from dental pulp are probably more similar to well-defined multipotent Mesenchymal/progenitor cells than stromal cells isolated from periodontal ligament with respect to their surface characteristics.

**Tri-lineage differentiation potential of DPSCs and PDLSCs**

Dental pulp stromal cells and PDLSCs were tested for their multi-lineage connective tissue differentiation potential by subjecting these cells to adipogenic, osteogenic and chondrogenic induction.

Dental pulp stromal cells as well as PDLSCs did not constitutively express the adipogenic commitment factor, PPARγ2, but under adipogenic conditions, induced expression of PPARγ2 as well as the early adipogenic gene, Lipoprotein lipase (LPL), was observed in DPSCs (Fig. 2A). Periodontal ligament stromal cells did not express any adipocyte-related genes under adipogenic induction conditions even at the end of 16 days. As compared with control cultures of adipose-derived mesenchymal stem cells (ASC), where robust oil droplet deposition was noted upon adipogenic induction, DPSCs and PDLSCs under identical induction conditions showed sluggish and rare oil deposition and the droplets were smaller and immature (Fig. 2B). This observation correlates with the lack of expression of Fatty acid binding protein 4 (FABP4; a terminal marker associated with mature adipocytes) in differentiated DPSC cultures (Fig. 2A).

Basal expression of RUNX2, master transcription factor for osteogenesis, was detected in both DPSCs and PDLSCs. An induction in RUNX2 levels was noted in PDLSCs upon differentiation, suggesting responsiveness to osteo-inductive factors (Fig. 2C). However, mid and terminal markers associated with osteocytes: Osteopontin (OPN) and Osteocalcin (OCN) were absent in both DPSC and PDLSC differentiation cultures. This was substantiated by lack of mineralization in DPSC and PDLSC cultures in contrast to robust Von Kossa staining of mineral deposits in BM-MSC-derived osteogenic cultures (Fig. 2D). A change in morphology of DPSC differentiation cultures was noted at the end of 18 days in induction media (Fig. 2D). Generation of osteoblast and odontoblast precursors engages similar signalling pathways; thus, in the absence of appearance of any terminal osteo-specific markers in DPSCs, it is possible that the change in morphology could be as a result of generation of odontoblast precursors (Fig. S1). Surprisingly, both DPSCs and PDLSCs express DMP1 (dentin matrix protein 1) and PDLSCs express DSPP (dentin sialophosphoprotein), a definitive terminal marker for odontogenesis. In addition, MSX1 (msh homeobox 1) and MSX2 (msh homeobox 2), known to be highly induced in pre-odontoblasts and functional odontoblasts, respectively, are induced in both DPSCs and PDLSCs under osteo-inductive condition, suggesting skewing towards dentinogenesis rather than osteogenesis (Fig. S1).

**SOX9**, a transcriptional factor associated with chondrogenesis, was expressed constitutively in both DPSCs and PDLSCs. Upon chondrogenic induction, both DPSCs and PDLSCs expressed the cartilage-specific core proteoglycan, Aggrecan (ACAN) and α chain of type X collagen (COL10A1), expressed specifically in chondrocytes during endo-chondrial ossification, suggesting terminal chondrogenesis (Fig. 2E). Further, strong safranin O staining of extracellular matrix was observed in induced cultures of DPSCs and PDLSCs (Fig. 2F).

Thus, DPSCs seem to be more multipotent as compared with PDLSCs, which are unipotent, as they completely lack any adipogenic and osteogenic potential.

**Immune-stimulatory ligand expression on DPSCs and PDLSCs in response to pro-inflammatory cytokines: IFNγ and TNFα**

Immune recognition involves binding of T cells to allo-antigens, predominated by MHC/HLA antigens and further rejection via the indirect pathway, as specified for canonical GVHD. Also productive immune responses are elicited by T cells only after robust signals from co-stimulatory ligands, like CD80/CD86, and immune-adhesion molecules like CD50/CD54 etc., contribute to the formation of a strong immune synapse [16]. Dental pulp stromal cells and PDLSCs express high HLA-ABC like most nucleated cells, and surface levels were induced further with IFNγ or TNFα in PDLSCs and IFNγ in DPSCs. HLA-DR was absent in DPSCs and PDLSCs, but was strongly induced in PDLSCs treated with IFNγ (Fig. 3). No expression of CD80, CD86 and CD11a was noted even after induction with
pro-inflammatory cytokines in consensus with published reports in BMSCs [11, 17, 18]. CD166/ALCAM, molecule involved in binding to activated leucocytes, was expressed in both the MSCs, but is not further induced by IFN-γ and TNF-α. CD54 is constitutively expressed at high levels and levels are further induced by both IFN-γ and TNF-α in DPSCs as well as PDLSCs. CD50 was not expressed in both the MSCs, but induction was noted upon IFN-γ treatment in PDLSCs only (Fig. 3). Bleak expression of CD11b was observed consistently in PDLSCs, but was not induced further by pro-inflammatory cytokines. Fas-FasL signalling is implicated in playing a key role in MSC-mediated immune-modulation [19]. CD95 (Fas) was expressed in both MSCs, but was not further induced with inflammatory stimuli (Fig. 3).

In a nutshell, PDLSCs differed from DPSCs in expression of immune-stimulatory ligands and differential response to pro-inflammatory cytokines.

**Immunogenicity of DPSCs and PDLSCs**

To check whether DPSCs and PDLSCs evoke an immune reaction from allogeneic immune cells, mitomycin C-treated MSCs were co-
cultured with allogeneic PBMCs in a one way MLR. BrdU incorporation was measured to check for any lympho-proliferative responses against allogeneic MSCs at the end of 6 days of co-culture. Mitomycin C-fixed allogeneic PBMCs, used as a positive control, elicited a strong responder PBMC proliferation (considered 100 RPU), whereas no BrdU incorporation was noted with autologous PBMCs. In comparison to allogeneic PBMCs, both DPSCs and PDLSCs elicited only sluggish proliferation (<25% as compared to stimulator allogeneic PBMCs) from allogeneic lymphocytes (Fig. 4). Interestingly, pre-exposure of both the MSCs to inflammatory cytokines, IFNγ and TNFα, also did not enhance immunogenicity despite an increase in immune-stimulatory ligand expression (Fig. 3). Immunogenicity of PDLSCs remained totally unaltered with or without prior exposure to either IFNγ or TNFα. However, ‘IFNγ-primed’ DPSCs did not elicit any proliferative responses from allogeneic PBMCs as compared with unprimed or TNFα-primed DPSCs, which at least elicited some minimal lympho-proliferation response. In totality, both unprimed and primed DPSCs and PDLSCs are hypo-immunogenic under allogeneic conditions, as what is reported for BMSCs [11, 17, 20, 21].

**Immune-modulatory potential of DPSCs and PDLSCs**

Peripheral blood mononuclear cells were stimulated with T cell mitogen, PHA, and the polyclonal T cell blast response was assessed in the presence and absence of MSC co-culture. As noted in Figure 5A, DPSCs clearly attenuated the T cell response in a dose-dependent

---

Fig. 3 Cell surface expression of immune-stimulatory ligands on dental pulp stromal cells (DPSCs) and periodontal ligament stromal cells (PDLSCs) in response to pro-inflammatory cytokines, IFNγ and TNFα. DPSCs and PDLSCs were treated with 150 U/ml of IFNγ and 10 ng/ml of TNFα for 72 hrs and stained with specific antibodies for flow cytometry analysis. Overlays depict relevant isotype control (Light grey histogram) and specific cell surface expression on untreated control (C), IFNγ-treated (I) and TNFα-treated (T) stromal cells. Data are representative of at least two independent experiments.
representative of at least two independent experiments.
mitomycinC-treated allogeneic PBMCs were considered 100%. Data are
incorporation was quantified by fluorimetry. Proliferation responses to
PBMCs at different dose ratios for 6 days and, subsequently, BrdU

immune-modulate better upon priming with either IFN-γ or TNFα. DPSCs
PDLSCs, unlike DPSCs, do not exhibit any immune-modulatory abili-
ties despite priming with inflammatory cytokines, whereas DPSCs
immune-modulate better upon priming with either IFN-γ or TNFα.

Discussion

Mesenchymal stromal cells from healthy adult oral tissues isolated
during cosmetic impaction could serve as easily accessible adult
MSC source for clinical applications. However, MSCs derived from
oro-facial tissues have not been adequately characterized, specifically
with respect to their allo-recognition properties most relevant at
the transplantation interface. Moreover, a thorough one-to-one
comparison of oral MSCs from identical donors for key MSC proper-
ties has not been evaluated in detail. An elaborate comparison of
DPSCs and PDLSCs for their surface characteristics reveals key dif-
f erences in the obligate MSC markers as well as a panel of stem
cell–associated marker: SSEA4 (Fig. 1C) in PDLSCs as compared
with DPSCs, whose profile is similar to bone marrow–derived stromal
populations. Low expression of CD105 is reported in heterogeneous
periodontal ligament stromal cultures and differences in the propor-
tion of CD105 were noted in deciduous and permanent
PDLSCs, with only 11.06% of cells expressing CD105 in adult
PDLSCs [22]. In addition, CD29, integrin β1, an important compo-
nent involved in adhering stem cells to their endogenous niches, is
absent on PDLSCs (Fig. 1C). As both the MSCs are passage-
matched and comparisons have been made from MSCs from same
donors, these differences in the surface characteristics could be
more intrinsic to the cell type rather than as a result of culture
variations, thus obligating the need for a unique phenotypic finger-
print for each stromal cell type.

Intrinsic differences in the tissue regeneration capacity and sponta-
naneous differentiation potential of in vitro cultured PDLSCs, DPSCs
and BMSCs are reported. When in vitro cultured PDLSCs, DPSCs and
BMSCs were transplanted subcutaneously in immune-compromised
mice, PDLSCs formed cementum-like tissue, DPSCs formed dentin
and BMSCs generated typical bone-like structures [23]. When a
comparative check on the multipotency of DPSCs and PDLSCs was con-
ducted by subjecting these cells to osteo-, adipo- and chondrogenic
inductive stimuli, both MSCs robustly responded to chondrogenic
stimuli with up-regulation of terminal genes associated with chondro-
genesis (Fig. 2E) and chondrocyte-specific matrix deposition
(Fig. 2F). However, differences in both osteogenic and adipogenic
potential were noted and, markedly, none of the cell types exhibited
the robust adipogenic potential and osteogenic potential of ASCs and
BMSCs respectively (Fig. 2A–D). Dental pulp stromal cells responded
to adipogenic cues and gave rise to cells with immature miniscule
droplets, indicating a pre-adipocyte stage, whereas PDLSCs were
completely unresponsive to adipogenic stimuli. This observation is in
consensus with reports that demonstrated incomplete and sluggish
adipogenic potential of DPSCs isolated by different methodologies
[24–26]. Mineralization and osteogenesis from DPSCs differ markedly
from what has been reported with BMSCs, with osteo-induced DPSCs
resembling osteo-dentin rather than a typical osteoblast [6]. Stem
cells from human exfoliated deciduous teeth, considered immature
DPSCs, unlike adult DPSCs, have robust osteogenic capacity and also
give rise to bone upon in vivo transplantation, unlike DPSCs, which
give rise to dentin[27]. Periodontal ligament stromal cells have even
lesser osteogenic potential than DPSCs and do not form mineralized
nodules and calcium deposits [23].

In the present study, despite induction of early osteogenic mark-
ers under osteogenic conditions, both DPSCs and PDLSCs were
detoured towards odontoblast differentiation (Fig. S1). Periodontal
ligament stromal cells as well as DPSCs might require additional sig-
nalling impetus from pathways like Notch to establish terminal differ-
etiation to osteoblasts [28]. Although several reports in the literature
indicate osteogenic potential of DPSCs, comparative gene expression
studies with osteoblast-like cells generated from DPSCs and normal
osteoblasts derived from BMSCs indicated many distinct molecular
differences and mineralization patterns resembled osteo-dentin [29].
The other reason for unresponsiveness of PDLSCs to osteo- and adi-
pogenic induction could be the absence of CD105; fractionation of
PDLSCs based on CD105 sorting has been reported to alter adipogenic potential in adult PDLSCs, emphasizing the need for progenitor fractionation to achieve optimum differentiation [22].

An assessment of detailed immune properties of DPSCs and PDLSCs revealed differences in expression of immune-adhesive ligands and adhesion molecules involved in inflammatory cell recruitment and migration, like CD50 (Fig. 3). Bone marrow stromal cells and other MSCs have been reported to exhibit a hypo-immune profile with total absence of co-stimulatory ligands, CD80 and CD86 expression even upon exposure to pro-inflammatory cytokines, and lack of co-stimulatory support to T cells is one of the main causes for MSC immune-evasiveness [11, 17, 20, 21]. In contrast to DPSCs, PDLSCs express immune-adhesive ligands: CD50 and CD11b, co-stimulatory ligand CD80 and HLA-DR, when induced with either IFN-γ or TNF-α, suggesting that PDLSCs respond to inflammatory cytokine stimulation like fibroblasts and conventional antigen-presenting immune cells. In a MLR, remotely mimicking the in vivo allogeneic GVHD response, both IFN-γ/TNF-α-primed and unprimed DPSCs as well as PDLSCs do not elicit robust lymphocyte proliferation as reported for BMSCs (Fig. 4). However, DPSCs and PDLSCs differed drastically in their capacity to immune-modulate ongoing T cell blast responses. Priming with either IFN-γ or TNF-α enhanced immune-modulation capacity of DPSCs (Fig. 5B), as reported for BMSCs [30]. This is of particular significance as transplantation of primed DPSCs, rather than naive DPSCs, could be more beneficial to achieve better resolution of inflammation and repair. Surprisingly, PDLSCs, both primed and unprimed, failed to attenuate polyclonal T cell blast responses. In totality, PDLSCs are evidently different from DPSCs as well as other MSCs with respect to response to pro-inflammatory cytokines, expression of immune-stimulatory ligands and their inability to immune-modulate ongoing lympho-proliferative responses. Periodontal ligament stromal cells could be similar to fibroblasts with respect to their inability to immune-modulate, whereas DPSCs are closer to other MSCs with reported immune-modulatory abilities.

There is a huge lacuna in our understanding of genes that pinpoint the exact differences between differentiated fibroblasts and multipotent MSCs, with more than 90% overlap in the surface phenotype of both the cell types. Both immature MSCs and mature fibroblasts coexist in the tissue and isolation procedures based on simple adherence do not distinguish them. In fact, clonal analysis of parent and daughter clones of multipotent MSCs in culture indicates a hierarchical loss of multipotency with emergence of bipotent and unipotent progenitors and ultimate restriction to a fibroblast state [31]. Interestingly, recent evidence suggests that even well-characterized, dermal fibroblast lines exhibit some tri-lineage differentiation potential to osteo-, adipo- and chondrogenic lineages. However, fibroblast lines
have been shown to lack or exhibit poor immune-suppression/immune-modulation abilities in comparison to MSCs [32]. Even the response pattern of MSCs and fibroblasts to inflammatory cytokines with respect to induction of immune-stimulatory ligands differs. Fibroblasts attain antigen presentation ability and pro-inflammatory activity upon exposure to pro-inflammatory cytokines, whereas the immune-suppressive/immune-modulatory activity is further enhanced upon exposure to pro-inflammatory cytokines [32]. The surprising lack of immune-modulation ability in PDLCSCs, unlike DPSCs and BMSCs [11, 17, 20], in our study could also be explained because of heterogeneous progenitor subsets differing in immune properties existing within the isolated mesenchymal cells. Of prime importance is the lack of CD105+ population in PDLCSCs (Fig. 1A). The expression of CD105 has been correlated with higher multipotency, hepatic trans-differentiation potency in adipose tissue-derived MSCs [33]. Similarly amniotic MSCs have been reported to harbour subsets having both immune-suppressive and immune-stimulation abilities depending on the absence and presence of HLA-DR, even though both these populations fail to elicit an allogeneic T cell response [34]. Thus, a thorough analysis of immune properties of stromal cells isolated from different tissues could impart an additional handle to demarcate therapeutic multipotent MSCs from fibroblasts, which are co-isolated with MSCs in vitro.

In a nutshell, this study indicates that stromal cells from dental pulp and periodontal ligament, although isolated from the same donors, have distinct mesenchymal properties with unique multi-lineage potency, surface characteristics pertaining to existence of unique subsets in the heterogeneity, respond differently to inflammatory stimuli and do not harbour identical immune-modulatory abilities. The identity and function of a ‘universal’ MSC in vivo remains an enigma and lack of definitive markers for prospective isolation of MSCs from all sources further adds to the uncertainty [8]. Under this scenario, in addition to ISCT-defined functional and phenotypic assessment for MSCs, a thorough evaluation of immune characteristics of MSCs from different niches, akin to that of BMSCs, would help define clinically beneficial MSCs.

Acknowledgements

This study was funded by Department of Science and technology (Project No. SR/FT/LS-183/2009). We thank Manipal University for providing the basic infrastructure for conducting the study. We are grateful to Dr. K.V. Anujith Kumar for critical review of the manuscript and encouragement throughout the study. Divya Gopalakrishnan helped us to standardize DPSC and PDLCSC isolation procedures.

Conflicts of interest

The authors have no conflict of interest in the present study.

Author contribution

Anoop B Vasandan and Shilpa Rani Shankar performed and interpreted most of the experiments and contributed equally to the study. Priya Prasad and Sowmya Jahnani contributed to the differentiation experiments and were of immense technical help. Professor R R Bhonde provided intellectual support. The work was conceived, designed, interpreted and written by Prasanna SJ.

Supporting information

Additional Supporting Information may be found in the online version of this article:

Figure S1 Expression of preodontoblast/odontoblast-associated transcripts in DPSC and PDLCSC cultures subjected to osteogenic induction.

Table S1 Primer pairs used to evaluate odontogenic differentiation potential of DPSCs and PDLCSCs by RT-PCR.

References

1. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8: 315–7.
2. Chang YJ, Shih DT, Tseng CP, et al. Disparate mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow and umbilical cord blood. Stem Cells. 2006; 24: 679–85.
3. Hsieh JY, Fu YS, Chang SJ, et al. Functional module analysis reveals differential osteogenic and stemness potentials in human mesenchymal stem cells from bone marrow and Wharton’s jelly of umbilical cord. Stem Cells Dev. 2010; 19: 1895–1910.
4. Strioga M, Viswanathan S, Darinskas A, et al. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived Mesenchymal stem and stromal cells. Stem Cells Dev. 2012; 21: 2724–52.
5. Al-Nabaheen M, Vishnubalaji R, Ali D, et al. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev. 2013; 9: 32–43.
6. Huang GT, Gronthos S, Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. J Dent Res. 2009; 88: 792–806.
7. Rodriguez-Lozano FJ, Insauti CL, Iniesta F, et al. Mesenchymal dental stem cells in regenerative dentistry. Med Oral Patol Oral Cir Bucal. 2012; 17: 1062–67.
8. Tolar J, Le Blanc K, Keating A, et al. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells. 2010; 28: 1446–55.
9. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol. 2013; 91: 19–26.
10. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008; 2: 141–50.

© 2013 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
11. Prasanna SJ, Gopalakrishnan D, Shankar SR, et al. Pro-inflammatory cytokines, IF-Ngamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS ONE. 2010; 5: 9016.

12. Wu KH, Tsai C, Wu HP, et al. Human application of ex-vivo expanded umbilical cord-derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplant. 2013; 22: 2041–51.

13. Wu KH, Sheu JN, Wu HP, et al. Cotransplantation of umbilical cord-derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: a pilot study. Transplantation. 2013; 95: 773–7.

14. Baksh D, Davies JE, Zandstra PW. Soluble factor cross-talk between human bone marrow-derived hematopoietic and mesenchymal cells enhances in vitro CFU-F and CFU-O growth and reveals heterogeneity in the mesenchymal progenitor cell compartment. Blood. 2005; 106: 3012–9.

15. Mafi P, Indocha S, Mafi R, et al. Adult mesenchymal stem cells and cell surface characterization - a systematic review of the literature. Open Orthop J. 2011; 5: 253–60.

16. Ali JM, Bolton EM, Bradley JA, et al. Allorecognition pathways in transplant rejection and tolerance. Transplantation. 2013; 96: 681–88.

17. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogenic immune cell responses. Blood. 2005; 105: 1815–22.

18. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res. 2006; 312: 2169–79.

19. Akikiya K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand/-FAS-mediated T cell apoptosis. Cell Stem Cell. 2012; 10: 544–55.

20. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99: 3838–43.

21. Rasmusson I, Ringdén O, Sundberg B, et al. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res. 2005; 305: 33–41.

22. Silverio KG, Rodrigues TL, Coletta RD, et al. Mesenchymal stem cell properties of periodontal ligament cells from deciduous and permanent teeth. J Periodontol. 2010; 81: 1207–15.

23. See BM, Miura M, Gronthos S, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet. 2004; 364: 149–55.

24. Zhang W, Walboomers XF, Shi S, et al. Multilineage differentiation potential of stem cells derived from human dental pulp after cryopreservation. Tissue Eng. 2006; 12: 2813–23.

25. Sonoyama W, Liu Y, Yamaza T, et al. Characterization of the apical papilla and its residing stem cells from human immature permanent teeth: a pilot study. J Endod. 2008; 34: 166–71.

26. Hilkens P, Gervois P, Fanton Y, et al. Effect of isolation methodology on stem cell properties and multilineage differentiation potential of human dental pulp stem cells. Cell Tissue Res. 2013; 353: 65–78.

27. Miura M, Gronthos S, Zhao M, et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci. 2003; 100: 5807–12.

28. Osathanon T, Manokawinchoke J, Nowwaro N, et al. Notch signaling is involved in neurogenic commitment of human periodontal ligament-derived mesenchymal stem cells. Stem Cells Dev. 2013; 22: 1220–31.

29. Carinci F, Papaccio G, Laino G, et al. Comparison between genetic portraits of osteoblasts derived from primary cultures and osteoblasts obtained from human pulpal stem cells. J Craniofac Surg. 2008; 19: 616–25.

30. Polchert D, Sobinsky J, Douglas G, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008; 38: 1745–55.

31. Sarugaser R, Hanoun L, Keating A, et al. Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy. PLoS ONE. 2009; 4: 6498.

32. Blasi A, Martinu C, Balducci L, et al. Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential. Vasc Cell. 3: 5.

33. Banas A, Teratani T, Yamamoto Y, et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology. 2007; 46: 219–28.

34. Magatti M, De Munari S, Vertua E, et al. Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Stem Cells. 2008; 26: 182–92.